stoxline Quote Chart Rank Option Currency Glossary
  
Blue Water Vaccines, Inc. (BWV)
0.1802  -0.014 (-6.97%)    12-21 15:59
Open: 0.2
High: 0.2
Volume: 520,290
  
Pre. Close: 0.1937
Low: 0.1776
Market Cap: 3(M)
Technical analysis
2024-02-27 2:43:35 PM
Short term     
Mid term     
Targets 6-month :  0.39 1-year :  0.53
Resists First :  0.34 Second :  0.46
Pivot price 0.17
Supports First :  0.14 Second :  0.12
MAs MA(5) :  0.17 MA(20) :  0.18
MA(100) :  0.28 MA(250) :  0.71
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  17.9 D(3) :  12.9
RSI RSI(14): 45.5
52-week High :  1.58 Low :  0.14
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BWV ] has closed above bottom band by 37.1%. Bollinger Bands are 59.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.17 - 0.17 0.17 - 0.17
Low: 0.16 - 0.16 0.16 - 0.16
Close: 0.17 - 0.17 0.17 - 0.17
Company Description

Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.

Headline News

Mon, 18 Dec 2023
Proteomedix acquired by Blue Water Biotech to form Onconetix - The Pharma Letter

Tue, 17 Oct 2023
Blue Water Biotech names new CEO, CFO as company faces dual Nasdaq delisting notices - Cincinnati Business Courier - Cincinnati Business Courier

Sun, 30 Apr 2023
UT Health Science Center San Antonio Launches Chlamydia Vaccine Study - Precision Vaccinations

Thu, 20 Apr 2023
Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones - Yahoo Finance

Tue, 11 Oct 2022
Is Blue Water Vaccines Inc (BWV) a Loser in the Healthcare Sector? - InvestorsObserver

Thu, 28 Jul 2022
Should You Hold Blue Water Vaccines Inc (BWV) Stock Thursday Morning? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 19 (M)
Shares Float 14 (M)
Held by Insiders 17.6 (%)
Held by Institutions 23.4 (%)
Shares Short 23 (K)
Shares Short P.Month 60 (K)
Stock Financials
EPS -1.09
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.56
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -30.3 %
Return on Equity (ttm) -101.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.75
Qtrly Earnings Growth 0 %
Operating Cash Flow -12 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -0.16
PEG Ratio 0
Price to Book value 0.29
Price to Sales 0
Price to Cash Flow -0.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android